Clinical Resources

African Multicenter Movement Disorder Grand Rounds

Live Online

Aug 20, 2026 - Dec 17, 2026

Experienced / Intermediate, Foundational / Beginner

1124<p>The MDS-AS African Multicenter Movement Disorder Grand Rounds aims to provide education in the field of movement disorders as well as mentor students from regional organizing centers. The course consists of 3-independent sessions organized in collaboration by multiple centers across the African region. Cases from the organizing centers and participants will be featured. This course covers fundamental movement disorder topics taught by internationally renowned movement disorder experts.<br /><strong><br />Registration Deadlines:&nbsp;</strong>Session 1: August 19, 2026 / Session 2: October 21, 2026 / Session 3: December 16, 2026<br /></p>Biomarkers, Biomarkers & Diagnostic Tools, Botulinum toxin, Chorea/Huntingtons Disease (HD), Clinical Trials, Corticobasal Syndrome (CBS)/Corticobasal Degeneration (CBD), Dopaminergic medications, Dystonia, Freezing of Gait (FOG), Genetics, Hyperkinetic Movement Disorders, Infusion therapy, Lewy-body dementia (LBD), Medications for motor complications, Medications for motor symptoms, Medications for non-motor symptoms, Multiple Systems Atrophy (MSA), Myoclonus, Neuroimaging, Neuropathology, Parkinson Disease/Hypokinetic Movement Disorders, Parkinson's Disease (PD), Progressive Supranuclear Palsy (PSP), Rating Scales, Therapies-Pharmacological, Tics/Tourettes syndrome (TS), Tremor/Essential Tremor (ET)4800.00https://education.movementdisorders.org/Detail/1124/MDS-AS-African-Multicenter-Movement-Disorder-Grand-Roundshttps://education.movementdisorders.org/Upload/ActivityImages/26AFRMULTI_202x108187522.png2026-08-20T00:00:002026-12-17T00:00:00<p><br></p><p><br></p>MDS Education<p><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/26AFRMULTI Online Course Schedule_no faculty_18062026024329.pdf" rel="noopener noreferrer" target="_blank"><img width="87" height="87" src="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/1742932457261_25032025025417.png" class="fr-fic fr-dii"></a><!--[endif]--><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/26AFRMULTI Online Course Schedule_no faculty_18062026024329.pdf" rel="noopener noreferrer" target="_blank"><strong>Course Schedule</strong></a><strong>&nbsp;</strong><!--[if !vml]--><!--[if !vml]--><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Faculty Listing_LMS_18062026025343.pdf" rel="noopener noreferrer" target="_blank"><img width="98" height="98" src="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/1742932457296_25032025025418.png" class="fr-fic fr-dii"></a><!--[endif]--><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Faculty Listing_LMS_18062026025343.pdf" rel="noopener noreferrer" target="_blank"><strong>Course Faculty</strong></a></p><p><br></p><p><em>Schedule as of June 18, 2026</em></p><p><br></p><p><strong>REGISTRATION FEES</strong><br><strong>Members &amp;</strong> <strong>Non-Members:</strong>&nbsp;$0 USD</p><p><br></p><p><strong>COURSE SCHEDULE<br>Session 1: Treatable hyperkinetic Movement Disorders: Do not miss</strong></p><p><em>Thursday, August 20, 2026</em><em>: 16:00 &ndash; 18:35 EEST</em></p><p><strong>Session 2: Parkinson&rsquo;s Disease and Its Mimics: How to differentiate&nbsp;</strong></p><p><em>Thursday, October 22, 2026</em><em>: 16:00 &ndash; 18:35 EEST</em><br><strong>Session 3: Hyperkinetic Movement Disorders: Clinical and imaging clues of diagnosis</strong></p><p><em>Thursday, December 17, 2026</em><em>: 16:00 &ndash; 18:35 EEST</em></p><p><br></p><p><em>To convert to your local time, please click here:&nbsp;</em><a href="https://www.timeanddate.com/worldclock/converter.html"><em>https://www.timeanddate.com/worldclock/converter.html</em></a><em>&nbsp;</em>&nbsp;</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:</p><p>1. Identify possible pharmacological and non-pharmacological therapies of PD and atypical parkinsonisms</p><p>2. Identify treatable causes of movement disorders</p><p>3. Identify and diagnose hyperkinetic movement disorders and manage appropriately&nbsp;</p><p>4. Identify clinical and investigational clues to diagnose movement disorders</p><p><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is intended for movement disorder specialists, general neurologists, movement disorders fellows, and residents.</p>0/Courses/African-Multicenter-Movement-Disorder-Grand-Rounds.htmAfrican Multicenter Movement Disorder Grand Rounds2026-07-13T12:00:52.15300Experienced / IntermediateFoundational / BeginnerLive OnlineBiomarkers &amp; Diagnostic ToolsHyperkinetic Movement DisordersParkinson Disease/Hypokinetic Movement DisordersTherapies-Pharmacological

Movement Disorders Journal (MDJ) Symposium: Neurobiology of Parkinson’s Disease

In-Person

Washington

Nov 13, 2026

Foundational / Beginner

1129<p>This symposium is organized by the editorial team of <em>Movement Disorder</em><em>s</em>, the official journal of the International Parkinson and Movement Disorder Society (MDS), as a satellite event of Neuroscience 2026, the annual meeting of the Society for Neuroscience. The MDJ Symposium will explore the biological underpinnings of Parkinson&rsquo;s disease, the neurobiological basis for current and emerging treatments, and the mechanisms responsible for disease complications and adverse responses to therapy.</p><p><strong>REGISTRATION DEADLINE</strong>: November 6, 2026<strong></strong></p>Animal models, Autoimmune, Basal Ganglia, Basic/Translational Neuroscience, Biomarkers, Biomarkers & Diagnostic Tools, Environmental Risk factors, Etiology & Pathophysiology, Gene Therapies, Genetics, Microbiome, Neuroimaging, Neuropathology, Parkinson Disease/Hypokinetic Movement Disorders, Parkinson's Disease (PD), Rating Scales, Synucleinopathy, Tauopathy3600.00https://education.movementdisorders.org/Detail/1129/Movement-Disorders-Journal-(MDJ)-Symposium:-Neurobiology-of-Parkinson’s-Diseasehttps://education.movementdisorders.org/Upload/ActivityImages/MDJ25_202x108428176.jpg2026-11-13T00:00:002026-11-13T00:00:00Washington, District of Columbia<p><br></p><p><br></p><p><a class="fr-file" href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/2026 MDJ Symposium Schedule_01072026124709.pdf" target="_blank">2026 MDJ Symposium Schedule.pdf</a></p>MDS Education<p><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/2026%20MDJ%20Symposium%20Schedule_01072026124709.pdf" rel="noopener noreferrer" target="_blank"><img width="87" height="87" src="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/1752005535651_08072025031214.png" class="fr-fic fr-dii"></a><!--[endif]--><strong><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/2026%20MDJ%20Symposium%20Schedule_01072026124709.pdf" rel="noopener noreferrer" target="_blank"><strong>Course Schedule</strong><strong>&nbsp;</strong><!--[if !vml]--><!--[endif]--></a> <!--[if !vml]--><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/5.%20Faculty%20Listing%20(w%20Photos)_01072026103914.pdf" rel="noopener noreferrer" target="_blank"><img width="98" height="98" src="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/1752005535687_08072025031214.png" class="fr-fic fr-dii"></a><!--[endif]--><a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/5.%20Faculty%20Listing%20(w%20Photos)_01072026103914.pdf" rel="noopener noreferrer" target="_blank"><strong>Course Faculty</strong></a></strong></p><p><em>Schedule as of July 1, 2026</em></p><p><br></p><p><strong>REGISTRATION FEES</strong><br><strong>Members:</strong>&nbsp;$30 USD<br><strong>Non-Members*:</strong>&nbsp;$45 USD</p><p>*<em>Non-members wishing to apply for MDS Membership to receive the MDS Member rate for this course will need to apply for membership no later than 2 weeks in advance of the close of registration.</em></p><p><a href="https://s3-us-east-2.amazonaws.com/mds-lms/FroalaFiles/VISA%20STATEMENT%20CANCELLATION%20LANGUAGE_24012024041714.pdf">Click here to view the MDS Regional Course Cancellation Policy &amp; Visa Assistance Information</a></p><p><br></p><p><strong>COURSE VENUE</strong></p><p>The Westin DC Downtown</p><p>999 9th Street Northwest</p><p>Washington, DC 20001</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:</p><p>1. Describe the networks responsible for the control of movement in PD, including the somato-cognitive action network, the cingulo-opercular network, and striatonigral projections.<br>2. Understand selective neurodegeneration as it applies to PD in terms of vulnerability, astrocytic dysfunction, and neurodevelopmental origins of disease.<br>3. Report the lifestyle and environmental factors that influence PD, such as interactions between &alpha;-synuclein polymorphisms and the microbiome, the disease-modifying effects of exercise, and other impactful contributors.<br>4. Appreciate the manuscript submission opportunities afforded by the translational scientific scope of the peer-reviewed journal <em>Movement Disorders</em>.</p><p><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is intended for students, postdocs, faculty, and others interested in translational research aspects of PD.</p>Washington0/Courses/Movement-Disorders-Journal-MDJ-Symposium-Neurobiology-of-Parkinsons-Disease1.htmMovement Disorders Journal (MDJ) Symposium: Neurobiology of Parkinson’s Disease2026-07-01T15:00:49.84700Foundational / BeginnerIn-PersonBasic/Translational NeuroscienceBiomarkers &amp; Diagnostic ToolsEtiology &amp; PathophysiologyParkinson Disease/Hypokinetic Movement Disorders

Journal CME 41.07: Automating Subthalamic Deep Brain Stimulation Programming with Evoked Resonant Neural Activity in Parkinson’s Disease

On Demand

60 Minutes

Experienced / Intermediate

1128<p>The Journal CME 41.07 article aims to investigate the feasibility and acute motor benefit of STN-DBS programming, guided by intraoperatively recorded evoked resonant neural activity (ERNA) in patients with PD.</p>Deep brain stimulation, Parkinson Disease/Hypokinetic Movement Disorders, Parkinson's Disease (PD), Therapies-SurgicalKanae J. Nagao, MBBS, FRACP601.00https://education.movementdisorders.org/Detail/1128/Journal-CME-41-07:-Automating-Subthalamic-Deep-Brain-Stimulation-Programming-with-Evoked-Resonant-Neural-Activity-in-Parkinson’s-Diseasehttps://education.movementdisorders.org/Upload/ActivityImages/Journal-CME562837664663.jpg2026-06-30T00:00:002027-06-30T00:00:00<p><strong>ACCREDITATION STATEMENT</strong></p><p>This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.</p><p><br></p><p><strong>CREDIT DESIGNATION STATEMENT</strong></p><p>The International Parkinson and Movement Disorder Society designates this activity for a maximum of 1 <em>AMA PRA Category 1 Credits&trade;</em>. Physicians should only claim credit commensurate with the extent of their participation.</p><p><br></p><p><strong>FACULTY DISCLOSURE</strong></p><p>All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available <a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Journal%20CME%2041.07%20-%20Disclosures_30062026101221.pdf" rel="noopener noreferrer" target="_blank"><u>HERE</u></a>. All relevant financial relationships have been mitigated in advance of this program.</p><p><br></p><p><strong>METHOD OF PARTICIPATION</strong></p><p>Each module will take approximately one (1) hour to complete. Upon reading the article, participants will take a post-test and must receive a grade of 75% or higher to pass. Participants are allowed multiple attempts to complete the post-test. Once the post-test is passed, participants are required to complete the module evaluation.</p><p><br></p><p><strong>SATISFACTORY COMPLETION</strong></p><p>Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.</p><p><br></p><p><strong>CONTENT VALIDITY STATEMENT</strong></p><p>All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.</p>MDS Education<p><strong>COURSE PURPOSE</strong></p><p>Journal CME highlights various articles covering relevant issues, developments and research topics in the area of movement disorders. Articles are selected from Movement Disorders, the official Journal of the International Parkinson and Movement Disorder Society.</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:</p><p>1. Understand the role of evoked resonant neural activity (ERNA) in deep brain stimulation programming<br>2. Assess the clinical performance of ERNA-guided programming compared with conventional programming methods<br>3. Evaluate the potential of ERNA-guided programming to improve deep brain stimulation outcomes in Parkinson&#39;s disease</p><p><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is intended for clinicians, other health professionals, researchers, policy makers from throughout the world, both MDS members and non-members, who interact with patients living with Movement Disorders.</p><p><br></p><p><strong>HARDWARE AND SOFTWARE REQUIREMENTS</strong></p><p>1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.</p><p>2. Compatible with Windows PC and MAC (256 MB of RAM or higher).</p><p>3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher.</p><p>4. Adobe Flash Player 12.0 (or higher).</p><p>5. Adobe Reader to print certificate.</p>0/Courses/Journal-CME-41.07-Automating-Subthalamic-Deep-Brain-Stimulation-Programming-with-Evoked-Resonant-Neural-Activity-in-Parkinsons-Disease.htmJournal CME 41.07: Automating Subthalamic Deep Brain Stimulation Programming with Evoked Resonant Neural Activity in Parkinson’s DiseaseJournal CME 41.072026-06-30T12:00:55.33300Experienced / IntermediateOn-DemandParkinson Disease/Hypokinetic Movement DisordersTherapies-Surgical

Journal CME 41.06: An Open-Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington’s Disease

On Demand

60 Minutes

Experienced / Intermediate

1127<p>The Journal CME 41.06 article aims to eassess the safety, pharmacokinetics (PK), pharmacodynamics, and clinical activity of ANX005 in patients with Huntington&rsquo;s disease (HD).</p>Chorea/Huntingtons Disease (HD), Clinical Trials, Hyperkinetic Movement Disorders, Therapies-PharmacologicalRajeev Kumar, MD601.00https://education.movementdisorders.org/Detail/1127/Journal-CME-41-06:-An-Open-Label-Phase-1b-Study-of-the-Safety,-Pharmacokinetics,-Pharmacodynamics,-and-Clinical-Activity-of-ANX005-in-Patients-with-Huntington’s-Diseasehttps://education.movementdisorders.org/Upload/ActivityImages/Journal-CME562837664663.jpg2026-06-30T00:00:002027-06-30T00:00:00<p><strong>ACCREDITATION STATEMENT</strong></p><p>This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.</p><p><br></p><p><strong>CREDIT DESIGNATION STATEMENT</strong></p><p>The International Parkinson and Movement Disorder Society designates this activity for a maximum of 1 <em>AMA PRA Category 1 Credits&trade;</em>. Physicians should only claim credit commensurate with the extent of their participation.</p><p><br></p><p><strong>FACULTY DISCLOSURE</strong></p><p>All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available <a href="https://d1t84l7yt030ad.cloudfront.net/FroalaFiles/Journal%20CME%2041.06%20-%20Disclosures_30062026092726.pdf" rel="noopener noreferrer" target="_blank"><u>HERE</u></a>. All relevant financial relationships have been mitigated in advance of this program.</p><p><br></p><p><strong>METHOD OF PARTICIPATION</strong></p><p>Each module will take approximately one (1) hour to complete. Upon reading the article, participants will take a post-test and must receive a grade of 75% or higher to pass. Participants are allowed multiple attempts to complete the post-test. Once the post-test is passed, participants are required to complete the module evaluation.</p><p><br></p><p><strong>SATISFACTORY COMPLETION</strong></p><p>Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.</p><p><br></p><p><strong>CONTENT VALIDITY STATEMENT</strong></p><p>All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.</p>MDS Education<p><strong>COURSE PURPOSE</strong></p><p>Journal CME highlights various articles covering relevant issues, developments and research topics in the area of movement disorders. Articles are selected from Movement Disorders, the official Journal of the International Parkinson and Movement Disorder Society.</p><p><br></p><p><strong>LEARNING OBJECTIVES</strong></p><p>Upon completion of this activity, learners will be able to:</p><p>1. Understand the role of complement inhibition in Huntington&#39;s disease</p><p>2. Assess the safety and preliminary clinical findings of ANX005</p><p>3. Evaluate the potential role of complement biomarkers in guiding Huntington&#39;s disease treatment</p><p><br></p><p><strong>INTENDED AUDIENCE</strong></p><p>This activity is intended for clinicians, other health professionals, researchers, policy makers from throughout the world, both MDS members and non-members, who interact with patients living with Movement Disorders.</p><p><br></p><p><strong>HARDWARE AND SOFTWARE REQUIREMENTS</strong></p><p>1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.</p><p>2. Compatible with Windows PC and MAC (256 MB of RAM or higher).</p><p>3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher.</p><p>4. Adobe Flash Player 12.0 (or higher).</p><p>5. Adobe Reader to print certificate.</p>0/Courses/Journal-CME-41.06-An-Open-Label-Phase-1b-Study-of-the-Safety-Pharmacokinetics-Pharmacodynamics-and-Clinical-Activity-of-ANX005-in-Patients-with-Huntingtons-Disease.htmJournal CME 41.06: An Open-Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington’s DiseaseJournal CME 41.062026-06-30T12:00:53.91000Experienced / IntermediateOn-DemandHyperkinetic Movement DisordersTherapies-Pharmacological